Medical Devices: Page 109
-
Zimmer takes electives hit in Q4, to spin off spine, dental units
"There's just no doubt that COVID, unfortunately, remains a challenge ... We're seeing the pandemic pressure and the surges continue and, frankly, worsen across pretty much all of our regions and markets," said CEO Bryan Hanson.
By Ricky Zipp • Feb. 5, 2021 -
BD posts better-than-expected COVID-19 test sales, but flagship Veritor revenues to slow
Coronavirus testing revenues totaled $867 million, primarily made up by sales for the Veritor antigen test. Execs cited new virus variants and the potential for further slowing in elective care for a conservative forecast.
By Ricky Zipp • Feb. 4, 2021 -
Explore the Trendline➔
Sara Silbiger via Getty ImagesTrendlineTop 5 stories from MedTech Dive
From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.
By MedTech Dive staff -
FDA appoints first medical device cybersecurity chief
University of Michigan professor Kevin Fu will serve a one-year term as acting cyber director at the Center for Devices and Radiological Health. Experts fear the chaos of the pandemic creates the perfect storm for hackers to exploit.
By Greg Slabodkin • Feb. 3, 2021 -
Boston Scientific sees COVID-19 electives pressure in Q1, recovery in second half
A hit of 7.7% in sales, driven by drops in neuromodulation and interventional cardiology, missed Wall Street expectations in the medtech's fourth quarter report.
By Ricky Zipp • Feb. 3, 2021 -
Death, injuries prompt FDA to call Boston Scientific ICD recall Class I event
The device giant began recalling the subcutaneous implantable defibrillator system electrode late last year after learning of 26 serious injuries and one death associated with the device.
By Nick Paul Taylor • Feb. 3, 2021 -
[Photograph]. Retrieved from Regional Health Command Atlantic.
From COVID-19 EUAs to 'insidious' remote care risks: ECRI's top 10 medtech hazards
Risks highlighted by the watchdog include FDA emergency use authorizations and the rapid adoption of telehealth, both of which have increased during the coronavirus pandemic.
By Susan Kelly • Feb. 1, 2021 -
4 key trends for medtech in 2021
With resurgence of the coronavirus and emergence of more contagious strains, COVID-19 challenges, but also opportunities, lie ahead for medical device and diagnostics companies.
By Greg Slabodkin • Jan. 29, 2021 -
Low Medicare EKG device draft slams iRhythm, stock price sinks by over 30%
Wall Street analysts questioned whether the lower-than-expected rates are final and what the prospects are for renegotiation. Shares of market leader iRhythm fell over 32% on Friday.
By Ricky Zipp • Updated Feb. 1, 2021 -
Deep Dive
CGM, insulin pump players look to 2021 as watershed year for diabetes wearables market
Insulet, Dexcom and Medtronic have product launches set for this year, and all look to capitalize on the recent skyrocketing of virtual care due to the coronavirus pandemic.
By Ricky Zipp • Jan. 29, 2021 -
Q&A
New iRhythm CEO on national pricing setback, Medtronic market expansion lessons
Michael Coyle will try to build off the cardiac monitoring company's recent success amid a telehealth boom. Shares have jumped by over 175% in the last 12 months.
By Ricky Zipp • Jan. 28, 2021 -
Hospitals lost $20B by pausing electives last year
The slowdown in elective care also hurt medtechs like Abbott and Johnson & Johnson. The industry expects declines to continue into 2021 after procedure volumes dropped again in the fourth quarter due to the virus resurgence.
By Shannon Muchmore • Jan. 28, 2021 -
Edwards' US TAVR sales fall as COVID-19 disrupts referrals
Analysts expected U.S. transcatheter aortic valve replacement sales to be flat in the fourth quarter but they fell by mid-single digits. Still, the company maintains guidance for global TAVR growth of 15-20% this year.
By Nick Paul Taylor • Jan. 28, 2021 -
Stryker falls short of Q4 sales amid electives pullback, robotics a bright spot
Double-digit growth in China was offset by hits in business in the U.S. and Europe. CEO Kevin Lobo told investors after volumes rebounded through October, large declines began in November and December.
By Ricky Zipp • Jan. 27, 2021 -
Biden invokes DPA to combat supply shortages, but experts say it's no 'magic wand'
AdvaMed early in the pandemic urged against using the Defense Production Act's powers, though some companies were more open. The device lobby last week asked the administration to coordinate with industry before taking action.
By Matt Leonard • Jan. 27, 2021 -
England's NHS moves to boost access to Quidel, Roche, other medtech products
To be a part of the National Health Services' MedTech Funding Mandate, companies must be able to make the claim that their products generate net savings in their first year of use.
By Nick Paul Taylor • Jan. 27, 2021 -
Abbott Q4 beat driven by COVID-19 test demand, devices come in flat
CEO Robert Ford said the company exited 2020 with "tremendous momentum" and forecast 35% growth for this year.
By Greg Slabodkin • Jan. 27, 2021 -
Surmodics drug-coated balloon on par with Medtronic's in study
The medtech is looking to distinguish itself from rivals with a lower dose, after a 2018 meta-analysis found a mortality risk for patients treated with paclitaxel-coated balloons or stents in the femoropopliteal artery of the leg.
By Susan Kelly • Jan. 26, 2021 -
Ventilators, imaging drive GE healthcare profits up 27% as procedures even out
"Regionally, public healthcare markets such as Europe and China have been stronger than private markets, particularly the U.S., India and Latin America," CFO Carolina Dybeck Happe told investors.
By Nick Paul Taylor • Jan. 26, 2021 -
J&J misses Wall Street on hips, knees and spine amid global elective care slowdown
CEO Alex Gorsky predicted challenges to persist in 2021 but suggested that improvement is in sight. "The resiliency and the ability of hospital systems to continue with elective surgeries has improved quite significantly," he said.
By Ricky Zipp • Jan. 26, 2021 -
Philips beats Q4 expectations as COVID-19 boosts connected care, slows procedures
The Dutch conglomerate will continue to be active on the M&A front, CEO Frans van Houten told investors, after striking two deals in the space over the past month worth more than $3.4 billion.
By Nick Paul Taylor • Jan. 25, 2021 -
Deep Dive
Abbott, Edwards focus on mitral valve as market projected to rival TAVR
Companies have zeroed in on TAVR in recent years, but in 2021 and beyond, experts and industry are looking to the mitral market for the next big structural heart splash.
By Ricky Zipp • Jan. 25, 2021 -
Healthcare funding shatters records in 2020, helped by COVID-19
Medical device startups raised roughly $6 billion in the fourth quarter, a high point over the last three years, according to a CB Insights report.
By Rebecca Pifer • Jan. 22, 2021 -
Intuitive braces for bumpy 2021 as COVID-19 resurgence hits robotics
The company, which gave details on its fourth quarter, is not giving guidance for the year amid uncertainty. Shares fell nearly 5% Friday morning.
By Nick Paul Taylor • Jan. 22, 2021 -
4 key trends for payers and providers in 2021
The COVID-19 crisis may spur speedier adoption of value-based care and partnerships between health systems and payers in the year ahead.
By Samantha Liss • Jan. 22, 2021 -
Boston Scientific bets on cardiac wearables with $925M Preventice buy
The deal is the latest in the fast-growing space, coming on the heels of Hillrom's $375 million BardyDx buy on Tuesday and Philips' $2.8 billion purchase of BioTelemetry last month.
By Ricky Zipp • Jan. 21, 2021